Tirzepatide vs semaglutide: dual vs single agonist comparison
One drug pulls one lever. The other pulls two. Here is what that actually changes.
TL;DR
- Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 + GIP). That dual-action is the main biological difference.
- Trial data shows tirzepatide produces larger average weight loss — about 20% vs 15% — but individual response varies widely.
- Both are available as compounded versions from licensed 503A pharmacies. Compounded versions are not FDA-approved.
What it is
Semaglutide (sold as branded Ozempic and Wegovy) is a GLP-1 receptor agonist (in plain English: a molecule that turns on the glucagon-like peptide-1 receptor, the body’s natural fullness signal). Tirzepatide (sold as branded Mounjaro and Zepbound) does both — it activates the GLP-1 receptor and the GIP receptor (in plain English: glucose-dependent insulinotropic polypeptide, a second gut hormone involved in insulin response). Think of semaglutide as turning on one switch. Tirzepatide turns on two switches at once.
How it works
Both drugs slow stomach emptying, increase the body’s natural insulin response after meals, and reduce appetite signals in the brain. The GIP-receptor activation that tirzepatide adds appears to support insulin sensitivity and may influence fat-cell behavior directly. The published mechanism is consistent across trials, per the SURMOUNT-1 study, 2022 for tirzepatide and the STEP-1 trial, 2021 for semaglutide.
Who asks about it
People ask this question after they have decided to consider a GLP-1 protocol and want to know if “the new one” is meaningfully better. Or after their primary-care clinician suggests one and they want context on the other. Most readers want a plain comparison without the prescription marketing pulling them one way.
What the research says
In the SURMOUNT-1 trial, tirzepatide produced average weight loss around 20% at 72 weeks. STEP-1 showed semaglutide around 15% over similar timelines. Side-effect profiles are similar — both cause nausea, occasional vomiting, and slow gastric emptying. About 4 in 10 patients on either drug experience nausea in the first 8 weeks. Direct head-to-head trials between the two compounds are limited as of 2026.
What to know before considering it
Both drugs require a prescription. Both require a clinician evaluation. Both carry the same general contraindications — personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, pregnancy. The protein-first protocol (resistance training plus adequate dietary protein) matters more on tirzepatide because the larger weight-loss numbers carry larger lean-mass risk if not managed.
The Halftime POV
We do not have a religious answer to “which one.” Both are real tools when used inside a real clinical relationship — labs, dose titration, follow-up, nutrition support, muscle preservation. The choice depends on the clinician’s assessment, the patient’s history, and access. We coordinate prescribing through licensed clinicians in our 46-state footprint.
Related reading:
- How GLP-1 peptides work: the triple action
- How tirzepatide activates GLP-1 and GIP simultaneously
- The protein-first protocol for GLP-1 patients
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
